Sales growth at constant exchange rates

STO-REC-STAT01M2KJT2 National
8%

North America · Q1 2026

Sales growth at constant exchange rates in the North America came in at 8% in Q1 2026 (Roche).

Original source
Publisher
Roche
Authority tier
T2 National
Locator
Group results
Retrieved
15 Sep 2026
Status
Verified

What the source says

In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas.

Verbatim extraction verified: The figure 8% is directly attested in the quoted passage (Group results).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG
MLA
Roche. "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...." 2026, https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG.
Chicago
Roche. "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...." 2026. https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG.
BibTeX
@misc{roche2026salesbjmgeg, author = {{Roche}}, title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\% sales growth at constant exchange rates; -2\% in CHF due to the significant a...}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG}, note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STAT01M2KJ T2 National

Primary Source

Publisher
Roche · homepage ↗
Authority tier
Tier 2 · National Official
Report
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...
Type
Press release
Published
23 July 2026
Locator
Group results
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
15 September 2026
Last revision
15 September 2026
Archival URI
/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG